145 related articles for article (PubMed ID: 9989567)
1. Diazepam treatment of early signs of exacerbation in schizophrenia.
Carpenter WT; Buchanan RW; Kirkpatrick B; Breier AF
Am J Psychiatry; 1999 Feb; 156(2):299-303. PubMed ID: 9989567
[TBL] [Abstract][Full Text] [Related]
2. Fluphenazine vs placebo supplementation for prodromal signs of relapse in schizophrenia.
Marder SR; Wirshing WC; Van Putten T; Mintz J; McKenzie J; Johnston-Cronk K; Lebell M; Liberman RP
Arch Gen Psychiatry; 1994 Apr; 51(4):280-7. PubMed ID: 8161288
[TBL] [Abstract][Full Text] [Related]
3. Combination alprazolam-neuroleptic treatment of the positive and negative symptoms of schizophrenia.
Wolkowitz OM; Pickar D; Doran AR; Breier A; Tarell J; Paul SM
Am J Psychiatry; 1986 Jan; 143(1):85-7. PubMed ID: 2867690
[TBL] [Abstract][Full Text] [Related]
4. Control group bias in randomized atypical antipsychotic medication trials for schizophrenia.
Woods SW; Gueorguieva RV; Baker CB; Makuch RW
Arch Gen Psychiatry; 2005 Sep; 62(9):961-70. PubMed ID: 16143728
[TBL] [Abstract][Full Text] [Related]
5. A placebo-controlled, double-blind comparison of clobazam and diazepam in the treatment of anxiety.
Jacobson AF; Goldstein BJ; Dominguez RA; Steinbook RM
J Clin Psychiatry; 1983 Aug; 44(8):296-300. PubMed ID: 6135690
[TBL] [Abstract][Full Text] [Related]
6. Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response.
Breier AF; Malhotra AK; Su TP; Pinals DA; Elman I; Adler CM; Lafargue RT; Clifton A; Pickar D
Am J Psychiatry; 1999 Feb; 156(2):294-8. PubMed ID: 9989566
[TBL] [Abstract][Full Text] [Related]
7. Placebo-controlled trial of glycine added to clozapine in schizophrenia.
Evins AE; Fitzgerald SM; Wine L; Rosselli R; Goff DC
Am J Psychiatry; 2000 May; 157(5):826-8. PubMed ID: 10784481
[TBL] [Abstract][Full Text] [Related]
8. A failed 6-week,randomized, double-blind, placebo-controlled study of once-daily extended release quetiapine fumarate in patients with acute schizophrenia: lessons learned.
Cutler AJ; Tran-Johnson T; Kalali A; Aström M; Brecher M; Meulien D
Psychopharmacol Bull; 2010; 43(4):37-69. PubMed ID: 21240151
[TBL] [Abstract][Full Text] [Related]
9. First generation antipsychotics switch with Risperidone in the treatment of chronic schizophrenic patients.
Popović I; Ravanić D; Popović V; Vladejić S; Stanojević A; Stojanović M
Psychiatr Danub; 2011 Dec; 23(4):384-8. PubMed ID: 22075740
[TBL] [Abstract][Full Text] [Related]
10. Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride. Amisulpride Study Group.
Danion JM; Rein W; Fleurot O
Am J Psychiatry; 1999 Apr; 156(4):610-6. PubMed ID: 10200742
[TBL] [Abstract][Full Text] [Related]
11. Risperidone in treatment-refractory schizophrenia.
Wirshing DA; Marshall BD; Green MF; Mintz J; Marder SR; Wirshing WC
Am J Psychiatry; 1999 Sep; 156(9):1374-9. PubMed ID: 10484947
[TBL] [Abstract][Full Text] [Related]
12. Negative signs and symptoms secondary to antipsychotics: a double-blind, randomized trial of a single dose of placebo, haloperidol, and risperidone in healthy volunteers.
Artaloytia JF; Arango C; Lahti A; Sanz J; Pascual A; Cubero P; Prieto D; Palomo T
Am J Psychiatry; 2006 Mar; 163(3):488-93. PubMed ID: 16513871
[TBL] [Abstract][Full Text] [Related]
13. Fluphenazine enanthate and fluphenazine decanoate in the treatment of schizophrenic outpatients: extrapyramidal symptoms and therapeutic effect.
Chouinard G; Annable L; Ross-Chouinard A
Am J Psychiatry; 1982 Mar; 139(3):312-8. PubMed ID: 6120655
[No Abstract] [Full Text] [Related]
14. Risperidone in the treatment of schizophrenia.
Marder SR; Meibach RC
Am J Psychiatry; 1994 Jun; 151(6):825-35. PubMed ID: 7514366
[TBL] [Abstract][Full Text] [Related]
15. Double-blind, placebo-controlled, multicenter trial of selegiline augmentation of antipsychotic medication to treat negative symptoms in outpatients with schizophrenia.
Bodkin JA; Siris SG; Bermanzohn PC; Hennen J; Cole JO
Am J Psychiatry; 2005 Feb; 162(2):388-90. PubMed ID: 15677608
[TBL] [Abstract][Full Text] [Related]
16. Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine.
de Lucena D; Fernandes BS; Berk M; Dodd S; Medeiros DW; Pedrini M; Kunz M; Gomes FA; Giglio LF; Lobato MI; Belmonte-de-Abreu PS; Gama CS
J Clin Psychiatry; 2009 Oct; 70(10):1416-23. PubMed ID: 19906345
[TBL] [Abstract][Full Text] [Related]
17. Effect size of symptom status in withdrawal of typical antipsychotics and subsequent clozapine treatment in patients with treatment-resistant schizophrenia.
Pickar D; Bartko JJ
Am J Psychiatry; 2003 Jun; 160(6):1133-8. PubMed ID: 12777272
[TBL] [Abstract][Full Text] [Related]
18. Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial.
Josiassen RC; Joseph A; Kohegyi E; Stokes S; Dadvand M; Paing WW; Shaughnessy RA
Am J Psychiatry; 2005 Jan; 162(1):130-6. PubMed ID: 15625211
[TBL] [Abstract][Full Text] [Related]
19. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder.
Potkin SG; Saha AR; Kujawa MJ; Carson WH; Ali M; Stock E; Stringfellow J; Ingenito G; Marder SR
Arch Gen Psychiatry; 2003 Jul; 60(7):681-90. PubMed ID: 12860772
[TBL] [Abstract][Full Text] [Related]
20. Neuroleptic responsivity of negative and positive symptoms in schizophrenia.
Breier A; Wolkowitz OM; Doran AR; Roy A; Boronow J; Hommer DW; Pickar D
Am J Psychiatry; 1987 Dec; 144(12):1549-55. PubMed ID: 3688278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]